Skip to main content

Advertisement

Log in

Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) plays vital roles in inflammatory and auto-immune diseases, but its correlations with disease risk and clinical features in inflammatory bowel disease (IBD) need further investigation. The present study intended to explore the correlation of ITIH4 with disease activity and inflammation, as well as its change after treatment in IBD patients.

Methods

Totally, 40 active Crohn’s disease (A-CD) patients, 40 clinical-remission CD (R-CD) patients, 40 active ulcerative colitis (A-UC) patients, 40 clinical-remission UC (R-UC) patients, and 40 health controls (HCs) were enrolled. ITIH4 in serum was assessed by ELISA.

Results

ITIH4 was lower in A-CD, R-CD, A-UC, and R-UC patients than in HCs (P < 0.001). Notably, ITIH4 reduced in A-CD patients than in R-CD patients (P = 0.017), and in A-UC patients compared with R-UC patients (P = 0.010). Besides, in A-CD patients, ITIH4 negatively correlated with tumor necrosis factor-alpha (TNF-α), interleukin (IL)-17A, IL-1β, C-reactive protein (CRP), and clinical disease activity index score (all P < 0.05). In A-UC patients, ITIH4 negatively correlated with TNF-α, IL-17A, IL-1β, IL-6, CRP, and Mayo score (all P < 0.05). However, in R-CD and R-UC patients, these correlations were less obvious than in A-CD and A-UC patients. ITIH4 was increased after treatment (all P < 0.05), and its expression at W12 after treatment was higher in response patients compared with no response patients in A-CD (P = 0.022) and A-UC groups (P = 0.038).

Conclusion

ITIH4 correlates with IBD susceptibility, active risk, inflammation level, and its elevation after treatment relates to clinical response in IBD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Abraham BP, Ahmed T, Ali T (2017) Inflammatory bowel disease: pathophysiology and current therapeutic approaches. Handb Exp Pharmacol 239:115–146

    Article  CAS  Google Scholar 

  2. Flynn S, Eisenstein S (2019) Inflammatory bowel disease presentation and diagnosis. Surg Clin North Am 99(6):1051–1062

    Article  Google Scholar 

  3. Park J, Park S, Lee SA et al (2021) Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management. Korean J Intern Med 36(5):1040–1048

    Article  Google Scholar 

  4. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ (2014) Immunopathology of inflammatory bowel disease. World J Gastroenterol 20(1):6–21

    Article  CAS  Google Scholar 

  5. Mak WY, Zhao M, Ng SC, Burisch J (2020) The epidemiology of inflammatory bowel disease: east meets west. J Gastroenterol Hepatol 35(3):380–389

    Article  Google Scholar 

  6. Sood A, Ahuja V, Midha V et al (2020) Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intest Res 18(4):355–378

    Article  Google Scholar 

  7. Mitoma H, Horiuchi T, Tsukamoto H, Ueda N (2018) Molecular mechanisms of action of anti-TNF-alpha agents - comparison among therapeutic TNF-alpha antagonists. Cytokine 101:56–63

    Article  CAS  Google Scholar 

  8. Chande N, Townsend CM, Parker CE, MacDonald JK (2016) Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 10(10):CD000545

  9. Clarke WT, Feuerstein JD (2019) Colorectal cancer surveillance in inflammatory bowel disease: practice guidelines and recent developments. World J Gastroenterol 25(30):4148–4157

    Article  Google Scholar 

  10. Gecse KB, Vermeire S (2018) Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol 3(9):644–653

    Article  Google Scholar 

  11. Oligschlaeger Y, Yadati T, Houben T (2019) Inflammatory bowel disease: a stressed “gut/feeling”. Cells 8(7):659

  12. Misselwitz B, Juillerat P, Sulz MC et al (2020) Emerging treatment options in inflammatory bowel disease: Janus kinases, stem cells, and more. Digestion 101(Suppl 1):69–82

    Article  CAS  Google Scholar 

  13. Chandler KB, Brnakova Z, Sanda M et al (2014) Site-specific glycan microheterogeneity of inter-alpha-trypsin inhibitor heavy chain H4. J Proteome Res 13(7):3314–3329

    Article  CAS  Google Scholar 

  14. Kashyap RS, Nayak AR, Deshpande PS et al (2009) Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke. Clin Chim Acta 402(1–2):160–163

    Article  CAS  Google Scholar 

  15. Choi-Miura NH, Takahashi K, Yoda M et al (2000) The novel acute phase protein, IHRP, inhibits actin polymerization and phagocytosis of polymorphonuclear cells. Inflamm Res 49(6):305–310

    Article  CAS  Google Scholar 

  16. Li L, Choi BC, Ryoo JE et al (2018) Opposing roles of inter-alpha-trypsin inhibitor heavy chain 4 in recurrent pregnancy loss. EBioMedicine 37:535–546

    Article  Google Scholar 

  17. Osada A, Matsumoto I, Mikami N et al (2021) Citrullinated inter-alpha-trypsin inhibitor heavy chain 4 in arthritic joints and its potential effect in the neutrophil migration. Clin Exp Immunol 203(3):385–399

    Article  CAS  Google Scholar 

  18. Kawaguchi H, Matsumoto I, Osada A et al (2018) Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis. Arthritis Res Ther 20(1):66

    Article  Google Scholar 

  19. Gersemann M, Wehkamp J, Stange EF (2012) Innate immune dysfunction in inflammatory bowel disease. J Intern Med 271(5):421–428

    Article  CAS  Google Scholar 

  20. Forbes A, Escher J, Hebuterne X et al (2017) ESPEN guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr 36(2):321–347

    Article  Google Scholar 

  21. Nie J, Zhao Q (2020) Lnc-ITSN1-2, derived from RNA sequencing, correlates with increased disease risk, activity and promotes CD4(+) T cell activation, proliferation and Th1/Th17 cell differentiation by serving as a ceRNA for IL-23R via sponging miR-125a in inflammatory bowel disease. Front Immunol 11:852

    Article  CAS  Google Scholar 

  22. Farkas K, Rutka M, Golovics PA et al (2016) Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis 10(11):1273–1278

    Article  Google Scholar 

  23. Filippi MD (2019) Neutrophil transendothelial migration: updates and new perspectives. Blood 133(20):2149–2158

    Article  CAS  Google Scholar 

  24. Garcia-Gil FA, Lampreave F, Fuentes-Broto L et al (2010) Inter-alpha-trypsin inhibitor heavy chain 4 as a marker of acute rejection in pancreas allotransplantation in pigs. Transplant Proc 42(8):3063–3069

    Article  CAS  Google Scholar 

  25. Shi X, Ohta Y, Liu X et al (2019) Acute anti-inflammatory markers ITIH4 and AHSG in mice brain of a novel Alzheimer’s disease model. J Alzheimers Dis 68(4):1667–1675

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jian Ma.

Ethics declarations

Informed consent

The written informed consents were gathered from all subjects. The study was permitted by Institutional Review Board.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 16 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wen, N., Zhao, N., Xu, H. et al. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment. Ir J Med Sci 191, 2105–2111 (2022). https://doi.org/10.1007/s11845-021-02837-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-021-02837-3

Keywords

Navigation